Our findings confirm that targeting CDC7 and TCN1 facilitates the improvement of barrier function in airway epithelial cells, epidermal keratinocytes, and intestinal epithelial cells in vitro, thereby providing promising therapeutic targets for diseases characterized by epithelial barrier dysfunction.
Liang et al. (Fri,) studied this question.